Skip navigation
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCastro, Rui-
dc.contributor.authorClementi, Gian Luca-
dc.contributor.authorMacDonald, Glenn-
dc.date.accessioned2008-05-30T21:30:09Z-
dc.date.available2008-05-30T21:30:09Z-
dc.date.issued2003-10-28-
dc.identifier.urihttp://hdl.handle.net/2451/27326-
dc.description.abstractRecent empirical evidence has suggested a positive association between various measures of investor protection and financial markets’ development, and between financial markets’ development and economic growth. We introduce investor protection in a simple extension of the two-period overlapping generations model of capital accumulation and study how it affects economic growth. Investor protection is positively related to risk-sharing. As is standard in models of investment with risk-averse agents, better protection (better risk sharing) results in a larger demand for capital. This is the demand effect. A second effect, which we call the supply effect, follows from general equilibrium restrictions. For a given aggregate capital stock, better protection (i.e., a higher demand schedule) implies a higher interest rate. The aggregate resource constraint then implies lower income for the entrepreneurs (the younger cohort). As a result, current savings and the supply of capital in the following period decrease. It turns out that the strength of the supply effect is greater, the tighter the restrictions on capital flows. Therefore our model predicts that the positive effect of investor protection on growth is stronger for countries with lower restrictions. We find that the data provides some support for this prediction.en
dc.language.isoen_USen
dc.relation.ispartofseriesS-MF-03-18en
dc.subjectOptimal Financing Contractsen
dc.subjectInvestor Protectionen
dc.subjectGrowthen
dc.subjectOverlappingen
dc.titleInvestor Protection, Optimal Incentives, and Economic Growthen
dc.typeWorking Paperen
Appears in Collections:Macro Finance

Files in This Item:
File Description SizeFormat 
S-MF-03-18.pdf442.19 kBAdobe PDFView/Open


Items in FDA are protected by copyright, with all rights reserved, unless otherwise indicated.